Working Groups

Standardisation of Bone Marker Assays as a part of the IFCC Committee Bone Metabolism (C-BM)

Members

Chairs: E Cavalier

Members:
IOF: K Åkesson, O Bruyère, C Cooper, R Eastell, J Foldes, P Garnero, NR Jørgensen, JA Kanis, P Khashayar, N Lane, M McClung, S Silverman
IFCC: HP Bhattoa, V Delatour, A Griesmacher, A Heijboer, M Lorentzon, C Sempos, C Sturgeon, C Ulmer, S Vasikaran, H Vesper

Aim

This working group seeks to identify consensus reference standard bone resorption marker and bone formation marker for fracture risk assessment and monitoring of osteoporosis treatment.

Objectives

  • Harmonisation and standardisation of selected bone markers (CTX and P1NP)
  • Clinical usefulness of bone turnover marker levels

Related content

Bone Turnover Markers Educational Course

Publications

  1. Cavalier, E., Eastell, R., Jørgensen, N.R. et al. A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcif Tissue Int (2021). https://doi.org/10.1007/s00223-021-00816-5
  2. Bhattoa HP, Cavalier E, Eastell R, Heijboer AC, Jørgensen NR, Makris K, Ulmer CZ, Kanis JA, Cooper C, Silverman SL, Vasikaran SD; IFCC-IOF Committee for Bone Metabolism. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. 2020 Dec 28:S0009-8981(20)30591-X. 
  3. Cavalier E, Lukas P, Bottani M, Aarsand AK, Ceriotti F, Coşkun A, Díaz-Garzón J, Fernàndez-Calle P, Guerra E, Locatelli M, Sandberg S, Carobene A; European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation and IOF-IFCC Committee on Bone Metabolism. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. 
    Osteoporos Int. 2020 Aug;31(8):1461-1470. doi: 10.1007/s00198-020-05362-8.
  4. Vasikaran SD, Bhattoa HP, Eastell R, Heijboer AC, Jørgensen NR, Makris K, Ulmer C, Kanis JA, Cooper C, Silverman S, Cavalier E. Harmonization of commercial assays for PINP; the way forward. 
    Osteoporos Int. 2020 Mar;31(3):409-412. doi: 10.1007/s00198-020-05310-6. 
  5. Cavalier, E., et al., A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clin Chem Lab Med, 2019. 
  6. Morris, H.A., et al., Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta, 2017. 467: p. 34-41.
  7. Johansson, H., et al., A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int, 2014. 94(5): p. 560-7.
  8. Vasikaran, S.D., C. Cooper, and J.A. Kanis, Recommendations for bone marker standards in osteoporosis: what, why and where to now? Ann Clin Biochem, 2011. 48(Pt 2): p. 91-2.
  9. Vasikaran, S., et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int, 2011. 22(2): p. 391-420.
  10. Vasikaran, S., et al., International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med, 2011. 49(8): p. 1271-4.